Whitehawk Therapeutics (NASDAQ:WHWK) Issues Earnings Results

by · The Markets Daily

Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01, FiscalAI reports.

Whitehawk Therapeutics Price Performance

Shares of NASDAQ:WHWK opened at $3.22 on Tuesday. Whitehawk Therapeutics has a 52 week low of $1.97 and a 52 week high of $5.49. The firm has a fifty day simple moving average of $3.66 and a two-hundred day simple moving average of $3.83.

Analysts Set New Price Targets

WHWK has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Leerink Partners began coverage on Whitehawk Therapeutics in a research report on Monday, July 13th. They issued an “outperform” rating and a $9.00 price objective on the stock. Stifel Nicolaus started coverage on Whitehawk Therapeutics in a research note on Wednesday, September 30th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Wall Street Zen upgraded Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Check Out Our Latest Stock Report on Whitehawk Therapeutics

Institutional Trading of Whitehawk Therapeutics

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Whitehawk Therapeutics during the second quarter valued at approximately $8,807,000. Montanova Capital LLC lifted its stake in shares of Whitehawk Therapeutics by 16.2% in the 2nd quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock valued at $19,694,000 after purchasing an additional 600,000 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Whitehawk Therapeutics in the 2nd quarter worth approximately $6,144,000. Two Sigma Securities LLC purchased a new position in shares of Whitehawk Therapeutics in the 2nd quarter worth approximately $46,000. Finally, Bank of America Corp DE bought a new position in shares of Whitehawk Therapeutics during the 2nd quarter valued at approximately $159,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.

Whitehawk Therapeutics Company Profile

(Get Free Report)

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.

Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.

Publicly available information about the company’s specific pipeline, operating geographies and leadership is limited.

Read More